Zevra Therapeutics (ZVRA) Notes Payables (2014 - 2020)

Zevra Therapeutics has reported Notes Payables for 7 years, with the latest figure at $65.9 million in Q3 2020.

• For the quarter ending Q3 2020, Notes Payables rose 881.24% year-over-year to $65.9 million; the trailing twelve-month figure through Sep 2020 stood at $65.9 million (up 881.24% YoY), and the FY2019 full-year result was $7.0 million, up 109.45% from the prior year.
• Notes Payables for Q3 2020 stood at $65.9 million, down from $67.3 million in the prior quarter.
• The five-year high for Notes Payables was $68.6 million in Q1 2020, with the low at $1.6 million in Q1 2016.
• Historically, Notes Payables has averaged $17.8 million across 5 years, with a median of $4.9 million in 2017.
• Annual changes were most pronounced in 2018 — Notes Payables changed 0.0% — and 2020, when it jumped 977.02%.
• Zevra Therapeutics' Notes Payables stood at $1.9 million in 2016, then soared by 72.52% to $3.3 million in 2017, then changed by 0.0% to $3.3 million in 2018, then surged by 109.45% to $7.0 million in 2019, then surged by 844.3% to $65.9 million in 2020.
• The last three Notes Payables figures came in at $65.9 million (Q3 2020), $67.3 million (Q2 2020), and $68.6 million (Q1 2020), per Business Quant data.